Orchid Pharma releases audio recording of earnings call
Orchid Pharma Limited has released the audio recording of its analysts and investors earnings call held on May 26, 2026. The disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The recording confirms the call was conducted via audio conference with no video recording available.

*this image is generated using AI for illustrative purposes only.
Orchid Pharma Limited has made available the audio recording of its analysts and investors earnings call held on May 26, 2026. The disclosure was submitted to the National Stock Exchange of India Limited and BSE Limited pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The earnings call was conducted through an audio conference at 04:30 P.M. (IST). The company confirmed that no video recording of the proceedings is available. The audio file can be accessed via a specific link provided on the corporate website.
The filing references SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. This circular mandates the dissemination of such recordings to ensure transparency and broader access to information shared during investor interactions.
The communication was signed by Kapil Dayya, Company Secretary & Compliance Officer of Orchid Pharma Limited. The intimation serves as a formal record of the event's occurrence and the availability of the associated audio file for stakeholders.
| Detail | Information |
|---|---|
| Event | Analysts/Investors Earnings Call |
| Date | May 26, 2026 |
| Time | 04:30 P.M. (IST) |
| Format | Audio Conference |
| Video Recording | Not Available |
Historical Stock Returns for Orchid Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.09% | +10.79% | +35.41% | -7.56% | +12.54% | -44.85% |
What key guidance or strategic updates did Orchid Pharma provide regarding its pipeline for FY2027?
How might the new SEBI disclosure mandate impact investor engagement strategies for other Indian pharmaceutical companies?
What are the expected market reactions to the financial results discussed during the call?


































